Developing a new ink for better endoscopic marking in colorectal cancer
Next-generation Tissue-Adhesive Endoscopic Tattoo Ink
['FUNDING_OTHER'] · ENDOTAT BIOTECHNOLOGIES LLC · NIH-11069963
This study is testing a new type of tattoo ink that helps doctors mark areas in the gut more accurately during procedures, which is really important for keeping an eye on and treating colorectal cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ENDOTAT BIOTECHNOLOGIES LLC (nih funded) |
| Locations | 1 site (PHOENIX, UNITED STATES) |
| Trial ID | NIH-11069963 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a next-generation tissue adhesive tattoo ink designed for use during endoscopic procedures. The new ink aims to improve the precision of marking lesions in the gastrointestinal tract, which is crucial for monitoring and treating colorectal cancer. By ensuring that the ink remains localized without diffusing into surrounding tissues, it seeks to enhance the effectiveness of follow-up procedures and surgeries. The project will involve testing the ink's performance in comparison to existing commercial options, particularly in terms of tissue retention and inflammatory response.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals undergoing colonoscopies or upper GI endoscopies, particularly those with lesions that require precise marking.
Not a fit: Patients who do not require endoscopic procedures or those without colorectal lesions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and effective monitoring of colorectal cancer, potentially improving patient outcomes and survival rates.
How similar studies have performed: Previous research has shown promise in developing improved endoscopic marking techniques, but this specific approach with tissue adhesive inks is relatively novel.
Where this research is happening
PHOENIX, UNITED STATES
- ENDOTAT BIOTECHNOLOGIES LLC — PHOENIX, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: REGE, KAUSHAL — ENDOTAT BIOTECHNOLOGIES LLC
- Study coordinator: REGE, KAUSHAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: American Cancer Society